Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
ALT - Altimmune, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.25
DETAILS
HIGH:
$10.00
LOW:
$2.50
MEDIAN:
$6.25
CONSENSUS:
$6.25
UPSIDE:
92.90%
Stock News
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,045,926 shares of the company's stock after purchasing an additional 762,223 shares during the quarter. Dimensional Fund Advisors
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune Q2 Earnings Call Highlights
Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial assessing pemvidutide in patients diagnosed with moderate to severe alcohol use disorder (AUD).
Altimmune's Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
Altimmune NASDAQ: ALT reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying the study met its primary endpoint and several secondary measures after 24 weeks of treatment.
Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
Altimmune said on Tuesday its experimental drug met the main goal of a mid-stage trial to help people with alcohol use disorder.
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD).
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Price Targets
Altimmune initiated with an Outperform at Leerink
$10.00
(was $3.00)
Thomas Smith
·
Leerink Partners
Altimmune upgraded to Neutral from Sell at Goldman Sachs
$2.50
(was $2.89)
Corinne Johnson
·
Goldman Sachs
Altimmune initiated with an Overweight at Barclays
$20.00
(was $6.18)
Barclays
Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report
$12.00
(was $10.23)
Patrick Trucchio
·
H.C. Wainwright
Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20
$20.00
(was $9.95)
Goldman Sachs
JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26
$26.00
(was $11.12)
JMP Securities
Jefferies Maintains Buy on Altimmune, Raises Price Target to $35
$35.00
(was $22.08)
Jefferies
Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler
$25.00
(was $18.94)
Yasmeen Rahimi
·
Piper Sandler
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50
$50.00
(was $17.66)
H.C. Wainwright